Asia-Pacific Anti-inflammatory Therapeutics Market Thumbnail Image

2023

Asia-Pacific Anti-inflammatory Therapeutics Market

Asia-Pacific Anti-inflammatory Therapeutics Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Class (Biologics, NSAIDs, Corticosteroids and Other), Indication (Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Others), and Distribution Channel (Hospital Pharmacy, Drug Stores & Retail Pharmacy, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Select an option
Author's: Linu Dash| Dhanashri Bhapkar | Roshan Deshmukh
Publish Date:

Get Sample to Email

Asia-Pacific Anti-inflammatory Therapeutics Market Statistics 2030:

The Asia-Pacific anti-inflammatory therapeutics market size was valued at $23.8 Billion in 2022, and is projected to reach $40.5 Billion by 2032, registering a CAGR of 5.4% from 2023 to 2032. Anti-inflammatory therapeutics are a group of drugs designed to reduce inflammation, a protective response by the body to injury or pathogens. These drugs act primarily by inhibiting pathways and molecules responsible for the inflammatory response. For instance, non-steroidal anti-inflammatory drugs (NSAIDs) work by blocking enzymes (COX-1 and COX-2) involved in prostaglandin synthesis that mediate inflammation. While NSAIDs and corticosteroids are the primary treatment option for inflammation, biologics are the newer class of medicines known to be effective in treating chronic inflammation.

Asia-Pacific Anti-inflammatory Therapeutics Market

However, there is still no cure for many chronic, autoimmune and respiratory inflammatory diseases. It highlights the impending need for effective and innovative anti-inflammatory medicines. Anti-inflammatory therapeutics are widely used to manage inflammatory conditions such as arthritis, psoriasis, multiple sclerosis, asthma, and others.

Market Dynamics

The Asia-Pacific anti-inflammatory therapeutics market growth is driven by increase in R&D activities for novel medication development, rise in prevalence of inflammatory diseases, such as psoriasis, arthritis, and respiratory diseases, and increase in approvals of new anti-inflammatory drugs. Through extensive research, scientists can identify potential drug targets, and conduct preclinical and clinical trials to test the safety and efficacy of new drugs. Such innovation leads to the creation of new anti-inflammatory drugs, which address unmet medical needs, improve treatment outcomes, and enhance patient care.

In addition, pharmaceutical companies invest in post-approval R&D activities to expand the therapeutic applications of anti-inflammatory therapeutics and develop new formulations or explore combination therapies. These strategies aim to enhance the clinical benefits of existing drugs and further drives the market growth. In addition, many pharmaceutical companies invest heavily in R&D, which is projected to boost the market growth. For instance, Sanofi S.A. has more than 10 products in the phase-1 and phase-2 evaluation for the treatment of asthma, psoriasis, ulcerative colitis, and others.

Further, Takeda Pharmaceuticals, a global leader in pharmaceuticals industry, has TAK-279 drugs for the treatment of psoriatic arthritis in the phase 2 evaluation. Thus, strong product pipeline is the key factor which is expected to create lucrative opportunities for the market growth during the forecast period.

In addition, the increase in product approvals by regulatory authorities also drives the growth of the Asia-Pacific anti-inflammatory therapeutics market. Approved drugs are marketed and sold to healthcare providers, which expand their accessibility to patients. This market expansion leads to increased revenue generation which, in turn, supports the growth of the Asia-Pacific anti-inflammatory therapeutics market. For instance, in May 2021, AbbVie Inc. a global pharmaceutical company receives approval for the additional indication of RINVOQ tablets for psoriatic arthritis in Japan. Therefore, such product approvals are expected to drive the growth of the Asia-Pacific anti-inflammatory therapeutics market during the forecast period.

Furthermore, availability of biologic drugs for the treatment of inflammatory conditions with potent mechanism of action also contribute towards the market growth. For instance, SKYRIZI is a biologic drug commercialized by AbbVie Inc., and is widely used for the treatment of rheumatoid arthritis.  

Increase in the prevalence of inflammatory diseases such as arthritis, inflammatory bowel disease, and others also supports the market growth. For instance, according to National Center for Biotechnology Information (NCBI), 2020, the prevalence of inflammatory bowel diseases is increasing in the Japan.

However, various side effects associated with corticosteroids and NSAIDs restrain the growth of the Asia-Pacific anti-inflammatory therapeutics market. NSAIDs, can lead to gastrointestinal issues such as ulcers, bleeding, or perforation. In addition, they also increase the risk of heart attack and stroke. On the other hand, long term use of corticosteroids can lead to osteoporosis. Thus, side-effects associated with inflammatory drugs hampers the market growth.

On the other hand, new product approvals and product launches are expected to create new opportunities for market growth during the forecast period. These product approvals will expand the treatment options for various inflammatory diseases such as arthritis, psoriasis and others.

The Asia-Pacific region's pharmaceutical and biotechnology sectors are somewhat affected by the continuing economic recession. The demand for pharmaceuticals, including anti-inflammatory therapies, has fluctuated as a result of decreased investment in industries such as pharmaceuticals and biotechnology. In addition, patients may skip routine check-ups for gastrointestinal problems and other disorders during a recession due to the economic downturn. This may lead to lower prescription rates and a decline in the demand for drugs. Thus, recession has a moderate impact on the Asia-Pacific anti-inflammatory therapeutics market.

Segmental Overview

The Asia-Pacific anti-inflammatory therapeutics market is segmented on the basis of drug class, indication, distribution channel, and region. On the basis of drug class, the market is segmented into biologics, NSAIDs, corticosteroids, and others. On the basis of indication, the market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, and inflammatory bowel disease, and others. By distribution channel, it is divided into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy. Country wise, the market is analyzed across Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific.

By Drug Class

The Asia-Pacific anti-inflammatory therapeutics market is segmented into biologics, NSAIDs, corticosteroids, and others. The biologics segment dominated the global market in 2022 and is expected to remain dominant throughout the forecast period. This is attributed to increase in new product approvals for biologics in Japan and other countries. Furthermore, biologics have higher efficacy and fewer off-target effects which makes them highly effective to treat inflammatory diseases. In addition, biologics are widely applicable in the treatment of various inflammatory conditions such as arthritis, ankylosing spondylitis, psoriasis, multiple sclerosis, and also contribute towards the growth of the segment. Further, biologics are widely preferred due to its specific action and fewer side effects than other anti-inflammatory drugs such as corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs).

Asia-Pacific Anti-inflammatory Therapeutics Market
By Drug Class
Your browser does not support the canvas element.

Biologics segment held a dominant position in 2022 and is anticipated to grow at a fastest rate during the forecast period.

By Indication

The Asia-Pacific anti-inflammatory therapeutics market is segregated into arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease, and others. The arthritis segment dominated the global market in 2022 and is anticipated to continue this trend during the forecast period. This is attributed to an increase in prevalence of rheumatoid arthritis and increase in number of people taking treatment for rheumatoid arthritis. Furthermore, launch of new biologic drugs for the treatment of arthritis also contribute towards the segment growth. Biologics are the drugs that effectively treat the arthritis thereby contributing towards the market growth.

Asia-Pacific Anti-inflammatory Therapeutics Market
By Indication
Your browser does not support the canvas element.

Arthritis segment held a dominant position in the market in 2022 and is anticipated to grow at a fastest rate during the forecast period.

By Distribution Channel

The Asia-Pacific anti-inflammatory therapeutics market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The drug stores & retail pharmacies segment dominated the global market in 2022 and is anticipated to remain dominant during the forecast period. This is attributed to the increase in hospitalization rate and surge in demand for anti-inflammatory therapeutics through retail pharmacies and drug stores. In addition, easy availability of over the counter NSAIDs also contribute towards the revenue generated by drug stores and retail pharmacies. Further, increase in the number of people taking treatments for the inflammatory diseases also boosts the growth of the market.

By Country

The Asia-Pacific anti-inflammatory therapeutics market is analyzed across Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific.

The presence of several major players, such as Pfizer Inc., Novartis AG, F. Hoffmann La-Roche Ltd., and Amgen Inc. and the rise in prevalence of various inflammatory conditions in the region drives the growth of the market. For instance, according to Narayana Health Organization the estimated prevalence of rheumatoid arthritis is 1% of the population in India. Increase in prevalence of rheumatoid arthritis leads to greater demand for ant-inflammatory drugs which drives the market growth. Moreover, easy accessibility and availability of anti-inflammatory therapeutics boost the growth of the market in this region.

Asia-Pacific region has a large population, and there has been an observed increase in the prevalence of cancer in recent years due to ageing population, lifestyle changes, and environmental factors. This has led to an increase in the number of patients suffering from cancer induced inflammatory conditions, which in turn increases the demand for anti-inflammatory therapeutics. For instance, in 2020, National Institute of Cancer Prevention and Research (NICPR), estimated that about 2.7 million people in India are living with cancer. In addition, growing adoption of anti-inflammatory therapeutics further propels the market growth. Moreover, development of pharmaceutical industry and increase in R&D activities boost the market growth in this region.  

China is the largest growing country in Asia-Pacific region owing to, high population of diseased patients. On the other hand, Japan, is expected to be the fastest growing country during the forecast period. This is attributed to an increase in new product launches and product approvals in this country for inflammatory disease treatment.

Competition Analysis

Competitive analysis and profiles of the major players in the Asia-Pacific anti-inflammatory therapeutics market, include Abbvie Inc., Amgen Inc., Pfizer Inc., GalaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Johnson and Johnson, Novartis AG, Eli Lilly and Company, Bayer AG, and AstraZeneca plc. Major players have adopted product approval and product launch as key developmental strategies to improve the product portfolio and gain strong foothold in the Asia-Pacific anti-inflammatory therapeutics industry.

Recent Product Approvals in the Asia-Pacific Anti-inflammatory Therapeutics Market

In February 2023, AbbVie Inc., a global pharmaceutical company received additional indication approval in Japan for RINVOQ tablets (upadacitinib hydrate) for the treatment of adult patients with axial spondyloarthritis who do not meet x-ray criteria. Such product launches will help the company to further expand its anti-inflammatory therapeutics portfolio.

Recent Product Launches in the Asia-Pacific anti-inflammatory therapeutics Market

In February 2023, AbbVie Inc. launched 360mg subcutaneous injection auto doser, new formulation of SKYRIZI in Japan.

In January 2023, AbbVie Inc., a global leader in pharmaceutical industry launches new SKYRIZI intravenous infusion 600mg formulation in Japan. Such product launches will help to expand the product portfolio of the company.

In November 2021, AbbVie Inc., a global pharmaceutical company launched new 45mg tablet formulation of RINVOQ in Japan. The launch of RINVOQ will help the company to gain a strong foothold in the anti-inflammatory therapeutics market.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the Asia-Pacific anti-inflammatory therapeutics market analysis from 2022 to 2032 to identify the prevailing the market opportunity in Asia-Pacific.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the Asia-Pacific anti-inflammatory therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the Asia-Pacific anti-inflammatory therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Asia-Pacific Anti-inflammatory Therapeutics Market Report Highlights

Aspects Details
Asia-Pacific Anti-inflammatory Therapeutics Market By Drug Class
By Drug Class
  • Biologics
  • NSAIDs
  • Corticosteroids
  • Others
Asia-Pacific Anti-inflammatory Therapeutics Market By Indication
By Indication
  • Arthritis
  • Respiratory Diseases
  • Multiple Sclerosis
  • Psoriasis
  • Inflammatory Bowel Disease
  • Others
Asia-Pacific Anti-inflammatory Therapeutics Market By Distribution Channel
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies
Key Market Players
Key Market Players

AbbVie Inc., GalaxoSmithKline PLC, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Eli Lilly and Company, Johnson and Johnson, Amgen Inc., Pfizer Inc.

Analyst Review

Anti-inflammatory therapeutics are medications designed to reduce or inhibit inflammation in the body. These medications are used to treat conditions like arthritis, asthma, or autoimmune disorders. These medications include range of drugs, from non-steroidal anti-inflammatory drugs (NSAIDs) to biologics, targeting various inflammatory pathways to alleviate symptoms and prevent tissue damage. Key factors such as surge in prevalence of autoimmune diseases and strong products pipeline are the key factors drives the growth of anti-inflammatory therapeutics market in the Asia-Pacific region.

Furthermore, the surge in product approvals by the key market players is expected to create opportunities for market growth. For instance, in February 2023, AbbVie received additional indication approval in Japan for RINVOQ Tablets (upadacitinib hydrate) for the treatment of adult patients with axial spondyloarthritis.

In addition, AbbVie Inc., a global pharmaceutical company, received approval for additional indication of RINVOQ tablets for psoriatic arthritis in Japan, in May 2021. Thus, new product approvals in the Asia-Pacific region further boost the market growth.

Author Name(s) : Linu Dash| Dhanashri Bhapkar | Roshan Deshmukh
Frequently Asked Questions?

The total market value of Asia-Pacific anti-inflammatory therapeutics marketis $23.8 billion in 2022.

The forecast period for Asia-Pacific anti-inflammatory therapeutics market is 2023-2032.

The market value of Asia-Pacific anti-inflammatory therapeutics market in 2032 is $40.5 billion.

The base year is 2022 in Asia-Pacific anti-inflammatory therapeutics market

Major key players that operate in the Asia-Pacific anti-inflammatory therapeutics market are Abbvie Inc., Amgen Inc., Pfizer Inc., GalaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Johnson and Johnson, Novartis AG, Eli Lilly and Company, Bayer AG, and AstraZeneca plc.

The biologics segment is the most influencing segment in the Asia-Pacific anti-inflammatory therapeutics market, which is attributed to strong availability of biologics drugs for the treatment of inflammatory diseases

The Asia-Pacific anti-inflammatory therapeutics market growth is driven by an increase in prevalence of inflammatory diseases, surge in R&D activities for developing novel anti-inflammatory drugs, and expansion of biologics

Anti-inflammatory therapeutics are the category of drugs are widely used to relieve pain and reduce inflammation in the body. These medications aim to prevent the symptoms and progression of inflammatory diseases.

Anti-inflammatory therapeutics are the category of drugs are widely used to relieve pain and reduce inflammation in the body. These medications aim to prevent the symptoms and progression of inflammatory diseases.

Loading Table Of Content...

Asia-Pacific Anti-inflammatory Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2023-2032